POZEN : Ranked as Second Most Efficient Pharma Company by SmarTrend

POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, announced today that Comtex SmarTrend has ranked POZEN as the second most efficient company in the pharmaceutical industry.

This evaluation was based on Revenue Per Employee (RPE) - a measure used by analysts to compare the productivity of companies in the same industry - and noted POZEN's RPE as $2.28 million. The other companies included in the top-five list were Columbia Laboratories, Depomed, ViroPharma and Pain Therapeutics.

As a next-generation pharmaceutical company, POZEN's philosophy is to own core capabilities and strategically partner for the rest. Its unique business model avoids some of the pitfalls of traditional drug development and commercialization, employing a small but expert team who lead the drug development strategy, partner selection and execution. The approach has delivered the approval of two self-invented products in two years - something almost no other small pharmaceutical company has done.


POZEN Inc. is a progressive pharmaceutical company that is transforming how the healthcare industry addresses unmet medical needs. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained U.S. Food and Drug Administration approval of two self-invented products in two years - something almost no other small pharmaceutical company has done. Funded by these two milestone/royalty streams, POZEN now is creating a portfolio of cost-effective, evidence-based integrated aspirin therapies designed to enable the full power of aspirin by reducing its gastrointestinal toxicity. The lead candidate PA32540 is being investigated for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced ulcers and has entered Phase 3 clinical trials. POZEN is retaining commercial control of the pipeline assets and will develop a 21st century sales and marketing organization using a new sales force model and digital communications. The Company's common stock is traded on The NASDAQ Stock Market under the symbol "POZN." For more detailed company information, including copies of this and other press releases, please visit www.pozen.com.

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.